{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:06:25Z","timestamp":1793912785592,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372852"],"award-info":[{"award-number":["82372852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82127807"],"award-info":[{"award-number":["82127807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZC20252573"],"award-info":[{"award-number":["GZC20252573"]}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["23ZR1427500"],"award-info":[{"award-number":["23ZR1427500"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07318-0","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:31:54Z","timestamp":1762781514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ginsenoside Rh2 as a novel PIN1 inhibitor disrupting the cancer stem cell-like phenotype in non-small cell lung cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3781-7271","authenticated-orcid":false,"given":"Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"10454","key":"7318_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404(10454):803\u201322.","journal-title":"Lancet"},{"issue":"9","key":"7318_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624\u201339.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"7318_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356.","journal-title":"Nat Med"},{"issue":"1","key":"7318_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-020-0181-3","volume":"5","author":"L Ouyang","year":"2020","unstructured":"Ouyang L, Yan B, Liu Y, Mao C, Wang M, Liu N, et al. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the Aryl hydrocarbon receptor. Signal Transduct Target Ther. 2020;5(1):78.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"7318_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41392-021-00555-x","volume":"6","author":"Q Xiong","year":"2021","unstructured":"Xiong Q, Jiang L, Liu K, Jiang X, Liu B, Shi Y, et al. miR-133b targets NCAPH to promote \u03b2-catenin degradation and reduce cancer stem cell maintenance in non-small cell lung cancer. Signal Transduct Target Ther. 2021;6(1):252.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"7318_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"7318_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704\u201315.","journal-title":"Cell"},{"issue":"1","key":"7318_CR8","doi-asserted-by":"publisher","first-page":"2310215","DOI":"10.1080\/19490976.2024.2310215","volume":"16","author":"G Dalmasso","year":"2024","unstructured":"Dalmasso G, Cougnoux A, Fa\u00efs T, Bonnin V, Mottet-Auselo B, Nguyen HT, et al. Colibactin-producing Escherichia coli enhance resistance to chemotherapeutic drugs by promoting epithelial to mesenchymal transition and cancer stem cell emergence. Gut Microbes. 2024;16(1):2310215.","journal-title":"Gut Microbes"},{"issue":"3","key":"7318_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2007","unstructured":"Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313\u201323.","journal-title":"Cell Stem Cell"},{"issue":"17","key":"7318_CR10","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.7150\/thno.20168","volume":"7","author":"D Xiang","year":"2017","unstructured":"Xiang D, Shigdar S, Bean AG, Bruce M, Yang W, Mathesh M, et al. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Theranostics. 2017;7(17):4071\u201386.","journal-title":"Theranostics"},{"issue":"2","key":"7318_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1039\/C4NP00080C","volume":"32","author":"AS Wong","year":"2015","unstructured":"Wong AS, Che CM, Leung KW. Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview. Nat Prod Rep. 2015;32(2):256\u201372.","journal-title":"Nat Prod Rep"},{"issue":"3","key":"7318_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jgr.2024.03.003","volume":"48","author":"JS Lee","year":"2024","unstructured":"Lee JS, Lee HY. Ginseng-derived compounds as potential anticancer agents targeting cancer stem cells. J Ginseng Res. 2024;48(3):266\u201375.","journal-title":"J Ginseng Res"},{"issue":"2","key":"7318_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000430115","volume":"36","author":"S Liu","year":"2015","unstructured":"Liu S, Chen M, Li P, Wu Y, Chang C, Qiu Y, et al. Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. Cell Physiol Biochem. 2015;36(2):499\u2013508.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"7318_CR14","doi-asserted-by":"publisher","first-page":"19752","DOI":"10.1038\/s41598-022-20075-0","volume":"12","author":"HJ Hwang","year":"2022","unstructured":"Hwang HJ, Hong SH, Moon HS, Yoon YE, Park SY. Ginsenoside Rh2 sensitizes the anti-cancer effects of Sunitinib by inducing cell cycle arrest in renal cell carcinoma. Sci Rep. 2022;12(1):19752.","journal-title":"Sci Rep"},{"issue":"1","key":"7318_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10020-024-00813-y","volume":"30","author":"X Liu","year":"2024","unstructured":"Liu X, Li J, Huang Q, Jin M, Huang G. Ginsenoside Rh2 shifts tumor metabolism from aerobic Glycolysis to oxidative phosphorylation through regulating the HIF1-\u03b1\/PDK4 axis in non-small cell lung cancer. Mol Med. 2024;30(1):56.","journal-title":"Mol Med"},{"issue":"5","key":"7318_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrc2107","volume":"7","author":"ES Yeh","year":"2007","unstructured":"Yeh ES, Means AR. PIN1, the cell cycle and cancer. Nat Rev Cancer. 2007;7(5):381\u20138.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"7318_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/cr.2014.109","volume":"24","author":"Z Lu","year":"2014","unstructured":"Lu Z, Hunter T. Prolyl isomerase Pin1 in cancer. Cell Res. 2014;24(9):1033\u201349.","journal-title":"Cell Res"},{"issue":"1","key":"7318_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/emmm.201302909","volume":"6","author":"A Rustighi","year":"2014","unstructured":"Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med. 2014;6(1):99\u2013119.","journal-title":"EMBO Mol Med"},{"key":"7318_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejphar.2018.10.043","volume":"842","author":"X Li","year":"2019","unstructured":"Li X, Wang H, Ding J, Nie S, Wang L, Zhang L, et al. Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells. Eur J Pharmacol. 2019;842:146\u201356.","journal-title":"Eur J Pharmacol"},{"key":"7318_CR20","doi-asserted-by":"publisher","first-page":"106456","DOI":"10.1016\/j.phrs.2022.106456","volume":"184","author":"W Wu","year":"2022","unstructured":"Wu W, Xue X, Chen Y, Zheng N, Wang J. Targeting Prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies. Pharmacol Res. 2022;184:106456.","journal-title":"Pharmacol Res"},{"issue":"18","key":"7318_CR21","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","volume":"184","author":"K Koikawa","year":"2021","unstructured":"Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021;184(18):4753\u2013e47714727.","journal-title":"Cell"},{"key":"7318_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fphar.2020.00904","volume":"11","author":"S Tanabe","year":"2020","unstructured":"Tanabe S, Quader S, Cabral H, Ono R. Interplay of EMT and CSC in cancer and the potential therapeutic strategies. Front Pharmacol. 2020;11:904.","journal-title":"Front Pharmacol"},{"key":"7318_CR23","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.drup.2020.100715","volume":"53","author":"N Erin","year":"2020","unstructured":"Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.","journal-title":"Drug Resist Updat"},{"key":"7318_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2018.12.010","volume":"444","author":"J Wang","year":"2019","unstructured":"Wang J, Zhang N, Han Q, Lu W, Wang L, Yang D, et al. Pin1 Inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to regorafenib via the Gli1\/Snail\/E-cadherin pathway. Cancer Lett. 2019;444:82\u201393.","journal-title":"Cancer Lett"},{"issue":"4","key":"7318_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/labinvest.2015.155","volume":"96","author":"Y Sakuma","year":"2016","unstructured":"Sakuma Y, Nishikiori H, Hirai S, Yamaguchi M, Yamada G, Watanabe A, et al. Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype. Lab Invest. 2016;96(4):391\u20138.","journal-title":"Lab Invest"},{"issue":"3","key":"7318_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/nar\/29.3.767","volume":"29","author":"SH Chao","year":"2001","unstructured":"Chao SH, Greenleaf AL, Price DH. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. Nucleic Acids Res. 2001;29(3):767\u201373.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"7318_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10495-016-1291-9","volume":"22","author":"S Sajadimajd","year":"2017","unstructured":"Sajadimajd S, Yazdanparast R. Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells. Apoptosis. 2017;22(1):135\u201344.","journal-title":"Apoptosis"},{"issue":"9","key":"7318_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41589-021-00786-7","volume":"17","author":"C Dubiella","year":"2021","unstructured":"Dubiella C, Pinch BJ, Koikawa K, Zaidman D, Poon E, Manz TD, et al. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nat Chem Biol. 2021;17(9):954\u201363.","journal-title":"Nat Chem Biol"},{"key":"7318_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jconrel.2017.11.031","volume":"269","author":"D Yang","year":"2018","unstructured":"Yang D, Luo W, Wang J, Zheng M, Liao XH, Zhang N, et al. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways. J Control Release. 2018;269:405\u201322.","journal-title":"J Control Release"},{"issue":"2","key":"7318_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.molcel.2011.03.005","volume":"42","author":"TH Lee","year":"2011","unstructured":"Lee TH, Chen CH, Suizu F, Huang P, Schiene-Fischer C, Daum S, et al. Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its Prolyl isomerase activity and cellular function. Mol Cell. 2011;42(2):147\u201359.","journal-title":"Mol Cell"},{"issue":"38","key":"7318_CR31","doi-asserted-by":"publisher","first-page":"16281","DOI":"10.1073\/pnas.0905653106","volume":"106","author":"G Bertolini","year":"2009","unstructured":"Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133\u2009+\u2009cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A. 2009;106(38):16281\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"7318_CR32","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41419-018-0972-4","volume":"9","author":"Y Mei","year":"2018","unstructured":"Mei Y, Liu YB, Cao S, Tian ZW, Zhou HH. RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt\/\u03b2-catenin signaling. Cell Death Dis. 2018;9(10):942.","journal-title":"Cell Death Dis"},{"issue":"8","key":"7318_CR33","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.7150\/thno.103722","volume":"15","author":"J Wang","year":"2025","unstructured":"Wang J, Liu L, Gao X, Liu X, Dai Y, Mao Z, et al. A novel pathway for stemness propagation and chemoresistance in non-small cell lung cancer via phosphorylated PKM2-loaded small extracellular vesicles. Theranostics. 2025;15(8):3439\u201361.","journal-title":"Theranostics"},{"issue":"7","key":"7318_CR34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc.2016.49","volume":"16","author":"XZ Zhou","year":"2016","unstructured":"Zhou XZ, Lu KP. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat Rev Cancer. 2016;16(7):463\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"7318_CR35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.molcel.2016.02.009","volume":"61","author":"X Li","year":"2016","unstructured":"Li X, Jiang Y, Meisenhelder J, Yang W, Hawke DH, Zheng Y, et al. Mitochondria-Translocated PGK1 functions as a protein kinase to coordinate Glycolysis and the TCA cycle in tumorigenesis. Mol Cell. 2016;61(5):705\u201319.","journal-title":"Mol Cell"},{"key":"7318_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2017.11.037","volume":"415","author":"J Wang","year":"2018","unstructured":"Wang J, Tian L, Khan MN, Zhang L, Chen Q, Zhao Y, et al. Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-\u03baB mediated epithelial-mesenchymal transition and stemness. Cancer Lett. 2018;415:73\u201385.","journal-title":"Cancer Lett"},{"issue":"7","key":"7318_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12272-021-01345-3","volume":"44","author":"H Jeon","year":"2021","unstructured":"Jeon H, Jin Y, Myung CS, Heo KS. Ginsenoside-Rg2 exerts anti-cancer effects through ROS-mediated AMPK activation associated mitochondrial damage and oxidation in MCF-7 cells. Arch Pharm Res. 2021;44(7):702\u201312.","journal-title":"Arch Pharm Res"},{"issue":"3","key":"7318_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12272-022-01377-3","volume":"45","author":"Y Jin","year":"2022","unstructured":"Jin Y, Huynh DTN, Heo KS. Ginsenoside Rh1 inhibits tumor growth in MDA-MB-231 breast cancer cells via mitochondrial ROS and ER stress-mediated signaling pathway. Arch Pharm Res. 2022;45(3):174\u201384.","journal-title":"Arch Pharm Res"},{"key":"7318_CR39","doi-asserted-by":"publisher","first-page":"155131","DOI":"10.1016\/j.phymed.2023.155131","volume":"121","author":"QR Hu","year":"2023","unstructured":"Hu QR, Huang QX, Hong H, Pan Y, Luo T, Li J, et al. Ginsenoside Rh2 and its octyl ester derivative inhibited invasion and metastasis of hepatocellular carcinoma via the c-Jun\/COX2\/PGE2 pathway. Phytomedicine. 2023;121:155131.","journal-title":"Phytomedicine"},{"key":"7318_CR40","doi-asserted-by":"publisher","first-page":"106988","DOI":"10.1016\/j.phrs.2023.106988","volume":"198","author":"MY Huang","year":"2023","unstructured":"Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, et al. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8(+) T cells via increasing intratumoral CXCL10. Pharmacol Res. 2023;198:106988.","journal-title":"Pharmacol Res"},{"key":"7318_CR41","doi-asserted-by":"crossref","unstructured":"Wu Y, Zhang J, Tian Y, Chi Shing Cho W, Xu HX, Lin ZX, et al. 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters. J Adv Res. 2024.","DOI":"10.1016\/j.jare.2024.09.006"},{"key":"7318_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.biopha.2017.09.033","volume":"96","author":"JH Kim","year":"2017","unstructured":"Kim JH, Kim M, Yun SM, Lee S, No JH, Suh DH, et al. Ginsenoside Rh2 induces apoptosis and inhibits epithelial-mesenchymal transition in HEC1A and Ishikawa endometrial cancer cells. Biomed Pharmacother. 2017;96:871\u20136.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"7318_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s13238-014-0027-2","volume":"5","author":"XX Guo","year":"2014","unstructured":"Guo XX, Li Y, Sun C, Jiang D, Lin YJ, Jin FX, et al. p53-dependent Fas expression is critical for ginsenoside Rh2 triggered caspase-8 activation in HeLa cells. Protein Cell. 2014;5(3):224\u201334.","journal-title":"Protein Cell"},{"issue":"12","key":"7318_CR44","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/biom12121896","volume":"12","author":"J-H Jeon","year":"2022","unstructured":"Jeon J-H, Park J-H, Jeon SY, Pang M, Choi M-K, Song I-S. Concomitant administration of red ginseng extract with lactic acid bacteria increases the plasma concentration of deglycosylated ginsenosides in healthy human subjects. Biomolecules. 2022;12(12):1896.","journal-title":"Biomolecules"},{"issue":"8","key":"7318_CR45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41419-020-02881-4","volume":"11","author":"Q Huang","year":"2020","unstructured":"Huang Q, Zhang H, Bai LP, Law BYK, Xiong H, Zhou X, et al. Novel ginsenoside derivative 20(S)-Rh2E2 suppresses tumor growth and metastasis in vivo and in vitro via intervention of cancer cell energy metabolism. Cell Death Dis. 2020;11(8):621.","journal-title":"Cell Death Dis"},{"issue":"6","key":"7318_CR46","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3892\/mmr.2021.12513","volume":"24","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yu S, Xing X, Qiao J, Yin Y, Wang J, et al. Ginsenoside Rh2 stimulates the production of mitochondrial reactive oxygen species and induces apoptosis of cervical cancer cells by inhibiting mitochondrial electron transfer chain complex. Mol Med Rep. 2021;24(6):873.","journal-title":"Mol Med Rep"},{"key":"7318_CR47","doi-asserted-by":"publisher","first-page":"1272667","DOI":"10.3389\/fcell.2023.1272667","volume":"11","author":"AM Battaglia","year":"2023","unstructured":"Battaglia AM, Sacco A, Vecchio E, Scicchitano S, Petriaggi L, Giorgio E, et al. Iron affects the sphere-forming ability of ovarian cancer cells in non-adherent culture conditions. Front Cell Dev Biol. 2023;11:1272667.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"7318_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13046-023-02641-0","volume":"42","author":"C De Vitis","year":"2023","unstructured":"De Vitis C, Battaglia AM, Pallocca M, Santamaria G, Mimmi MC, Sacco A, et al. ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis. J Experimental Clin Cancer Res. 2023;42(1):69.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"12","key":"7318_CR49","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s12272-016-0821-x","volume":"39","author":"SH Min","year":"2016","unstructured":"Min SH, Zhou XZ, Lu KP. The role of Pin1 in the development and treatment of cancer. Arch Pharm Res. 2016;39(12):1609\u201320.","journal-title":"Arch Pharm Res"},{"issue":"2","key":"7318_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7702","key":"7318_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","volume":"556","author":"I Pastushenko","year":"2018","unstructured":"Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition States occurring during EMT. Nature. 2018;556(7702):463\u20138.","journal-title":"Nature"},{"issue":"7","key":"7318_CR52","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","volume":"171","author":"SV Puram","year":"2017","unstructured":"Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al. Single-Cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017;171(7):1611\u2013e16241624.","journal-title":"Cell"},{"issue":"1","key":"7318_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1021\/acsnano.1c06022","volume":"16","author":"S Li","year":"2022","unstructured":"Li S, Li L, Lin X, Chen C, Luo C, Huang Y. Targeted Inhibition of tumor inflammation and tumor-platelet crosstalk by nanoparticle-mediated drug delivery mitigates cancer metastasis. ACS Nano. 2022;16(1):50\u201367.","journal-title":"ACS Nano"},{"issue":"1","key":"7318_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13046-020-01808-3","volume":"40","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Han Q, Zhao H, Zhang J. Promotion of epithelial-mesenchymal transformation by hepatocellular carcinoma-educated macrophages through Wnt2b\/\u03b2-catenin\/c-Myc signaling and reprogramming Glycolysis. J Exp Clin Cancer Res. 2021;40(1):13.","journal-title":"J Exp Clin Cancer Res"},{"issue":"13","key":"7318_CR55","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/0008-5472.CAN-13-2785","volume":"74","author":"ML Luo","year":"2014","unstructured":"Luo ML, Gong C, Chen CH, Lee DY, Hu H, Huang P, et al. Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer. Cancer Res. 2014;74(13):3603\u201316.","journal-title":"Cancer Res"},{"key":"7318_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1476-4598-11-73","volume":"11","author":"S Singh","year":"2012","unstructured":"Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR\/Src\/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2012;11:73.","journal-title":"Mol Cancer"},{"issue":"11","key":"7318_CR57","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1021\/acs.jmedchem.2c00472","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Liu Z, Wang Y, Gou S. Platinum(IV) prodrugs with cancer stem cell inhibitory effects on lung cancer for overcoming drug resistance. J Med Chem. 2022;65(11):7933\u201345.","journal-title":"J Med Chem"},{"key":"7318_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2018.04.008","volume":"428","author":"L MacDonagh","year":"2018","unstructured":"MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O\u2019Byrne KJ, et al. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 2018;428:117\u201326.","journal-title":"Cancer Lett"},{"issue":"1","key":"7318_CR59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13287-018-1072-1","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang X, Meng Q, Qiao W, Ma R, Ju W, Hu J, et al. miR-181b\/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC. Stem Cell Res Ther. 2018;9(1):327.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"7318_CR60","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1164\/rccm.201207-1180OC","volume":"186","author":"CT Yeh","year":"2012","unstructured":"Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012;186(11):1180\u20138.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07318-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:12:01Z","timestamp":1762884721000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07318-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7318"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07318-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were performed in accordance with ethical guidelines established by the Committee on Animal Research Ethics at Shanghai University of Medicine and Health Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1256"}}